Zepsyre (Lurbinectedin ) is an inhibitor of RNA polymerase II, which is commonly hyperactivated in SCLA, resulting in excessive transcription in tumor cells.
Inhibition by lurbinectedin is expected to decrease tumor cell proliferation primarily by inhibiting mitosis .
The United States Food and Drug Administration (FDA) granted lurbinectedin (PM1183) orphan drug status for the treatment of SCLC. This designation was based on a phase II multicenter basket study (NCT02454972) that assessed efficacy in 68 recurrent SCLC patients.
Among the 61 patients evaluable for efficacy, ORR was 39.3%, 7 patients had stable disease for more than 4 months after treatment, the overall clinical benefit rate was 50.8%, the rate of disease control was 73.8%, and median OS was 11.8 months.
An ongoing phase III trial of lurbinectedin plus doxorubicin vs. topotecan has completed accrual and should provide additional evidence in support of the efficacy of this agent in SCLC.
***********************************
En el Congreso de ASCO ( 1 Junio ) el Dr. Luis Paz Ares , en Presentación Oral , dará a conocer los resultados del ensayo con Zepsyre en Monoterapia para el Tratamiento de Cáncer de Pulmón de Células Pequeñas ( Microcítico ) .
Zepsyre (Lurbinectedin ) is an inhibitor of RNA polymerase II, which is commonly hyperactivated in SCLA, resulting in excessive transcription in tumor cells.
